Drugs / KD101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02819934 | May → Jun 2016 | obesity disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02462031 | Mar 2015 → Jan 2016 | obesity disorder | Kwang Dong Pharmaceutical co., ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01979380 | Dec 2013 → May 2014 | poisoning | Kwang Dong Pharmaceutical co., ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-09-23 | Kwang Dong Pharmaceutical co., ltd. | Regulatory 광동제약, 새로운 기전의 비만 치료제 1상 승인 ekdp.com ↗
광동제약은 새로운 기전의 비만치료제 KD101(프로젝트 명) 의 1상 임상시험계획(IND)을 식약처로부터 승인받고 후속 절차를 준비중이라고 29일 밝혔다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-09-23 | Kwang Dong Pharmaceutical co., ltd. | 광동제약, 새로운 기전의 비만 치료제 1상 승인 ekdp.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KD101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02819934 ↗ |
| Route | Oral | “200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning” NCT01979380 ↗ |